|
|
 |
Therion Biologics aims to transform cancer treatment by extending and improving quality of life.
Therion is at the forefront of developing a new class of biological therapies intended to train the body's own immune system to fight cancer without serious side effects. Therion's investigational products are often referred to as cancer vaccines because they use the same vaccine strategies that successfully eradicated infectious diseases, such as measles and polio, to fight cancer. Although traditional vaccines are designed to prevent disease, cancer vaccines are administered therapeutically to treat a disease that already exists. The pipeline chart below illustrates the status of studies being conducted by Therion.
Therion's vaccines deliver two components that are thought to: 1) stimulate the immune system to target cancer and 2) enhance and sustain the anti-cancer immune response. For over 10 years, Therion has been continually optimizing its vaccines to maximize the probability for downstream success. To date, Therion has evaluated its vaccines and vaccine components in over 700 patients in over 30 Phase I and Phase II clinical studies. This extensive clinical experience has consistently suggested that Therion's vaccine candidates are well tolerated. Common side effects include: injection site reactions, fatigue, chills and fever.
|
